Dolmen Engineering

Business Park Castlebar Unit 10, N5
F23TD77 Castlebar
IE
Dolmen Engineering
Foundation date
03/11/2014
Sector
#Supplier & EngineeringSubsector
- #Therapeutics - Small molecules
- #Pharma - Cell therapy
- #Pharma - Gene therapy
- #Pharma - Generics
- #Pharma - Molecular diagnostics
- #Pharma - Proteins
- #Pharma - Vaccines
- #Professional Services - Business development
- #Professional Services - IT services
- #Professional Services - Management consulting
- #Professional Services - Sales & Marketing
- #Supplier - APIs and excipients
- #Supplier - Laboratory engineering
- #Supplier - Laboratory equipment
- #Supplier - Medical devices
- #Supplier - Production engineering
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the eye
- #Endocrine - nutritional and metabolic diseases
- #Infectious and parasitic diseases
- #Injury - poisoning and certain other consequences of external causes
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Skin and subcutaneous tissue
Dolmen Engineering is an Engineering Consultancy specializing in the execution of projects in the Pharmaceutical and Life Sciences Industry.
Founded in 2014, we have expanded our expertise to address all aspects of innovative design solution integration. From Feasibility Analysis and Conceptual Design, Project Execution and Management, to Qualification and Validation, Dolmen has become a full-service provider to household names in the various Life Sciences sectors.
Whether a client is developing new manufacturing capabilities or optimizing existing processes, we have the expertise, agility, and flexibility to adapt to our client’s needs, developing effective lean solutions, improving performance, and optimizing return on investment.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2809 '22
Neurotechnologies
Event by: VIB -
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB
Latest news
More news-
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
3 hours ago
Read more
-
Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases
Tuesday June 28th 2022
Read more
-
MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis
Tuesday June 28th 2022
Read more
Jobs
More jobs-
05/07/22
Brussels
Postdoctoral position in cancer immunology and the tumor immune microenvironment
Permanent
VIB -
-